Joel Greenblatt’s Ultragenyx Pharmaceutical RARE Stock Holding History

Joel Greenblatt’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,478	Closed	-$349K	–	1484
2024 Q1	$349K	Hold	7,478	–	–	0.01%	1153
2023 Q4	$358K	Buy	+7,478	New	+$290K	0.01%	1087
2023 Q3	–	Sell	-15,822	Closed	-$730K	–	1400
2023 Q2	$730K	Sell	15,822 -3,039	-16%	-$141K	0.02%	859
2023 Q1	$756K	Buy	18,861 +9,779	+108%	+$420K	0.02%	830
2022 Q4	$421K	Buy	9,082 +3,176	+54%	+$125K	0.01%	942
2022 Q3	$245K	Buy	+5,906	New	+$304K	0.01%	1031
2021 Q1	–	Sell	-1,546	Closed	-$214K	–	1072
2020 Q4	$214K	Buy	+1,546	New	+$183K	0.01%	918
2019 Q2	–	Sell	-4,562	Closed	-$316K	–	1258
2019 Q1	$316K	Buy	+4,562	New	+$261K	﹤0.01%	982

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Joel Greenblatt's RARE Position: Q2 2024 in Review

Joel Greenblatt sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2024, closing a stake of 7,478 shares — an estimated $349K sold.

Joel Greenblatt first reported a position in RARE in Q1 2019 and held it in 8 quarters. The position peaked at $756K in Q1 2023. 275 funds tracked by Wall St. Rank hold RARE as of Q2 2024.

Joel Greenblatt reported no remaining Ultragenyx Pharmaceutical position as of Q2 2024 after selling out during the quarter.
Joel Greenblatt sold 7,478 Ultragenyx Pharmaceutical shares in Q2 2024, an estimated $349K.
Joel Greenblatt first reported a position in Ultragenyx Pharmaceutical in Q1 2019 and held it in 8 quarters.
Joel Greenblatt's Ultragenyx Pharmaceutical position peaked at $756K in Q1 2023.
275 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2024.

Based on Gotham Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.